Comparison of the efficacy of noninvasive positive pressure ventilation combined with and without budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in the treatment of acute exacerbations of Chronic Obstructive Pulmonary Disease.

Objective: Mechanical ventilation, such as noninvasive positive pressure ventilation (NIPPV), is often used to relieve the symptoms of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but its treatment effect is limited. This study explored the application effect of NIPPV combined with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) in AECOPD.

Methods: The clinical records of 152 patients with AECOPD treated in the First People's Hospital of Yongkang City from March 2023 to March 2024 were retrospectively selected and grouped based on the ventilation method used: simple NIPPV treatment (n=78) and NIPPV combined with BGF MDI (n=74). The primary outcome was improvement in oxygenation; the secondary outcomes were the recovery of body function and levels of inflammatory markers.

Results: After two weeks of treatment, the arterial partial pressure of carbon dioxide (PaCO2) in the combination group was significantly lower than in the NIPPV group, while the arterial partial pressure of oxygen (PaO2) and oxygenation index (OI) were significantly higher (P<0.05). The COPD Assessment Test (CAT) and St George's Respiratory Questionnaire (SGRQ) scores of the combined group were significantly lower, while the 6-minute walking test (6MWT) score was higher compared to the NIPPV group (P<0.05). The levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in the combined group were significantly lower compared to the NIPPV group (P<0.05).

Conclusions: NIPPV combined with BGF MDI has higher benefits than NIPPV alone for treating patients with AECOPD.